PD-1 Non-Small Cell Lung Cancer Market

Market Overview:

The 7 major PD-1 non-small cell lung cancer markets are expected to exhibit a CAGR of 6.54% during 2024-2034.

The PD-1 non-small cell lung cancer market has been comprehensively analyzed in IMARC's new report titled "PD-1 Non-Small Cell Lung Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". PD-1 non-small cell lung cancer refers to a specific type of oncological disease in which cancerous cells express the programmed death-ligand 1 (PD-L1) on their surface. In this condition, PD-L1 binds to PD-1 receptors on T cells and inhibits their activity, thereby suppressing the immune response against the tumors. The interaction allows cancerous cells to evade the body's defense processes and continue to grow and spread. Individuals suffering from the illness may experience persistent coughing, shortness of breath, fatigue, chest and bone pain, unintended weight loss, hoarseness or a change in voice, lack of appetite, difficulty swallowing, headaches, seizures, dizziness, etc. The diagnosis of this ailment is mainly based on the patient's characteristic features, medical history review, and physical examination. Additionally, molecular testing may be performed on the tumor tissue sample to aid in identifying specific genetic changes or mutations in the cancerous cells, including those related to PD-1 expression. Numerous imaging studies, such as chest X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI), positron emission tomography (PET) scans, etc., are commonly used to detect lung cancer and determine its stage.

The rising prevalence of genetic mutations and the escalating demand for therapies that can address gene defects associated with the disease are primarily driving the PD-1 non-small cell lung cancer market. Furthermore, the increasing utilization of immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for treating oncological conditions that have become resistant to conventional therapeutic techniques is acting as another significant growth-inducing factor. Apart from this, the widespread adoption of platinum-based chemotherapy coupled with anti-PD-1 antibodies, which allow a more robust and targeted response against cancerous cells by amplifying the immune reactions in patients, is further creating a positive outlook for the market. Moreover, numerous regulatory authorities are implementing favorable policies, like limiting the approval process to encourage the research and commercialization of anti-PD-1 therapy for lung cancer. This, in turn, is also augmenting the market growth. Additionally, the emerging popularity of next-generation sequencing techniques, a minimally invasive method for monitoring condition worsening, treatment response, and minimal residual disease after anti-PD-1 therapy, is expected to drive the PD-1 non-small cell lung cancer market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the PD-1 non-small cell lung cancer market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for PD-1 non-small cell lung cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the PD-1 non-small cell lung cancer market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the PD-1 non-small cell lung cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the PD-1 non-small cell lung cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current PD-1 non-small cell lung cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the PD-1 non-small cell lung cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the PD-1 non-small cell lung cancer market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the PD-1 non-small cell lung cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer across the seven major markets?
• What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of PD-1 non-small cell lung cancer by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with PD-1 non-small cell lung cancer across the seven major markets?
• What is the size of the PD-1 non-small cell lung cancer patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of PD-1 non-small cell lung cancer?
• What will be the growth rate of patients across the seven major markets?
   

PD-1 Non-Small Cell Lung Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for PD-1 non-small cell lung cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the PD-1 non-small cell lung cancer market?
• What are the key regulatory events related to the PD-1 non-small cell lung cancer market?
• What is the structure of clinical trial landscape by status related to the PD-1 non-small cell lung cancer market?
• What is the structure of clinical trial landscape by phase related to the PD-1 non-small cell lung cancer market?
• What is the structure of clinical trial landscape by route of administration related to the PD-1 non-small cell lung cancer market?